22:55 , May 11, 2018 |  BioCentury  |  Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May 8,...
19:57 , May 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

New Therapeutic Targets and Biomarkers: April 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April 2018. Therapeutic targets are defined as any protein, gene or other molecule...
21:46 , Apr 25, 2018 |  BC Innovations  |  Translation in Brief

Prostate prognosis

A Dana-Farber Cancer Institute team has uncovered previously unreported associations between prostate cancer and low-frequency mutations in 79 genes that could serve as prognostic markers for metastatic disease. The results, published this month in Nature Genetics,...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global biopharma...
19:16 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Galapagos reports Phase Ib data for GLPG1972 in OA

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported top-line data from a Phase Ib trial in 30 patients ages 50-75 with knee and/or hip osteoarthritis (OA) showing that three dose levels of once-daily oral GLPG1972 for four weeks...
19:42 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Musculoskeletal Mouse studies suggest activating ADAMTS1 could help treat muscle injury. In a mouse model of muscle injury, levels of ADAMTS1 were higher in the injured muscle than in the contralateral uninjured muscle. Also in...
18:01 , Sep 1, 2017 |  BC Week In Review  |  Company News

Servier gets rights to Galapagos' OA candidate

In July, Servier (Neuilly-sur-Seine, France) said it exercised its option for worldwide commercialization rights, excluding the U.S., to GLPG1972 (S201086) from Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG). Galapagos retains U.S. commercialization rights. Galapagos will receive a €6 million...
04:35 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

IdeS: Ph II discontinued

Hansa discontinued an open-label, U.K. Phase II trial evaluating a single IV dose of IdeS after preliminary data from 2 asymptomatic patients with acquired TTP showed a "non-favorable" risk-benefit profile. The company said that while...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

IdeS: Phase II started

Hansa began an open-label, U.K. Phase II trial to evaluate single doses of 0.25 and 0.5 mg/kg IV IdeS in up to 6 patients with acquired TTP and low ADAMTS13 activity who are asymptomatic. Hansa...
07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13)

Hematology INDICATION: Thrombocytopenia In vitro studies suggest a modified form of ADAMTS13 could help treat thrombotic thrombocytopenic purpura (TTP). Autoantibodies from TTP patients inhibit ADAMTS13-mediated cleavage of von Willebrand factor (vWF) by an unknown mechanism. Structural analysis...